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The International Symposium “Advances in Systems Biology in Neurosciences” was
held in February 2015 in Geneva. A hundred scientists with a variety of expertise
gathered around the theme of human brain complexity and cognitive disorders.
Through a series of lectures and poster sessions, the symposium showcased state-of-
the-art high-throughput biotechnologies, supercomputers and neuroimaging, and
illustrated the latest advances in systems approaches to tackle Neurosciences and
Neurodegenerative disorders. The meeting highlighted the power of big data to
understand complex pathologies and also the need for more open and integrated
data.
Keywords: Systems biology, Imaging, Data integration, Modeling, Alzheimer,
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Over the last two decades, research in life sciences experienced a paradigm shift, add-
ing to the very successful reductionist analysis of isolated entities (molecules, cells, or-
gans) the study of interacting entities, called “Systems Biology”. Neuroscience
pioneered the systems approaches and is now pushing the boundaries of multi-scale
descriptions, from the molecule to the disease [1]. The human brain contains about
100 billions neurons [2], connected by 1 quadrillion synapses. Understanding brain
function, and disorders, as well as designing treatments requires gathering enormous
amounts of heterogeneous data. The challenges faced range from collection and anno-
tation to storage and integration (Fig. 1).
On Friday, February 6, 2015 in Geneva was held the International Symposium “Ad-
vances in Systems Biology in Neurosciences”, funded by the European Commission
through the AgedBrainSYSBIO project and jointly sponsored by the Vital-IT/Swiss-
Prot groups of the Swiss Institute of Bioinformatics (SIB), Novartis and Roche. The
meeting brought together clinicians, biologists, bioinformaticians, and statisticians
from different European-funded consortia such as AgedBrainSYSBIO, SynSys, the
European flagship Human Brain Project (HBP), and also US projects such as the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Allen Institute for Brain
Science. This international assembly of scientists was gathered in the high-tech build-
ing that hosts the HBP and SIB on the Campus Biotech of Geneva (formerly Merck-
Serono). Through a series of lectures and poster sessions, the symposium showcased© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
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Fig. 1 Geneva Biotech campus
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gies, supercomputers and neuroimaging, and illustrated the latest advances in systems
approaches to tackle Neurosciences and Neurodegenerative disorders. This was an op-
portunity for more than one hundred researchers and students from academia and in-
dustry to gather and share their knowledge in the field. The first authors of this report
are students in partners of AgedBrainSYSBIO. Attendance to this meeting allowed
them to be exposed to the foremost research in the systems biology of neuronal sys-
tems. Professor Michel Simonneau (Centre de Psychiatrie et Neurosciences, INSERM
U894, coordinator of AgedBrainSYSBIO) and Ioannis Xenarios (SIB Group Leader,
head of Vital-IT and Swiss-Prot) opened the meeting with welcoming remarks (Fig. 2).
The first session, moderated by Dr Le Novère, from the Babraham Institute,
Cambridge, UK), began with a keynote presentation by Dr. Sean Hill, co-Director of
the Blue Brain Project [3] and co-Director of Neuroinformatics in the European Union
funded Human Brain Project (HBP) at the École Polytechnique Fédérale de Lausanne
(EPFL). This large project (involving more than 250 researchers), supported by EU in-
formation technology funding, aims to provide innovative tools to the global Neurosci-
ence community in order to model and simulate the human brain. Sean Hill, one of the
coordinators of this flagship European program, introduced the audience with an im-
pressive data infrastructure built over the first 10 years of work. Electrophysiological re-
cordings, gene expression patterns, morphological studies, among others, are stored
and integrated with rich semantic metadata in order to inform mathematical models of
neuronal circuits. He then presented preliminary simulations of the electrical behavior
of neocortical columns, built upon the compilation of the large amount of data de-
scribed above [4]. Such complex models require large amount of storage and comput-
ing power (the simulations are currently using a Blue Gene computer). The HBP still
faces significant challenges when developing a platform to generate and make access-
ible for the whole community the huge amount of data required for understanding the
entire brain function.
Dr. Yann Herault, head of the Institut Clinique de la Souris (ICS) and research group
leader at the Institut de Génétique Biologie Moléculaire et Cellulaire (IGBMC) in
Illkirch, France, presented the second lecture about a large mouse aneuploidy zoo. His
talk described efforts to decipher the physiopathology of Intellectual Disabilities [5]
using mouse models of human trisomy 21. A complete and standardized
Fig. 2 Sean Hill, from the EPFL (Lausanne, Switzerland)
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ulations) in order to understand the role of different chromosome 21 regions impli-
cated in cognitive defects. These mouse models helps understand the pathophysiology
of trisomy 21, and also of related neurological disorders.
Dr. Maksym V. Kopanitsa, from the biotechnology company Synome, a spin-off from
the Wellcome Trust Sanger Institute (Cambridge, UK) presented his company’s work.
Expert on high throughput analysis of synaptic function and cognition, he has been in-
volved in different European projects (EUROSPIN, SynSys, GENCODYS and
PharMEA). The company specializes in multiple electrophysiological recordings and
has developed useful scoring algorithms describing the importance of each protein in
synapse activity. Using mouse models mutated for genes encoding key proteins of pre-
and post-synaptic compartments, Synome aims to describe the role of each of these
proteins [6].
The last speaker of the first session was Dr Le Novère. To understand the function of
the synapse, and in particular its plasticity, at the molecular level, his group develops
mathematical models and numerical simulation. His presentation focused on the
response of synaptic protein kinases to calcium signals. He described in particular
mechanistic allosteric models of calmodulin, based on the thermodynamic equilibrium
between the two conformations of calmodulin’s lobes [7]. These models were then
placed in the context of the synapse, to obtain a proper simulation of calcium signal
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large detailed models of entire neurons [8]. Such models permit to integrate existing
knowledge and test our hypothesis about neuronal function.
Dr Jane Ann Driver from Brigham and Women’s Hospital (Boston, MA, USA)
opened the second session, chaired by Prof. Michel Simonneau. Dr. Driver’s talk shed
light on the correlation between different diseases and their impact. Epidemiological
evidences suggest an inverse association - that is a negative correlation - between the
presence of cancer and the most common neurodegenerative conditions, such as
Alzheimer’s disease (AD) and Parkinson’s Disease (PD) [9]. She underlined how difficult
it was to assess such association, due to many biases induced by treatments, lack of
reporting and cancer-induced death. She then presented results supporting the involve-
ment of Pin1, a protein known to promote cellular health by restoring phosphorylated
Tau and amyloid precursor protein to a functional state [10]. Dr. Driver also described
a mouse knock-out model for the gene encoding the Pin1 protein, cancer-resistant and
more sensitive to neurodegenerative and aging disorders. Understanding inverse co-
morbidities and predicting them is crucial to choose treatments. Their detection relies
on large epidemiological data. The more we have, the better the detection, understand-
ing and treatment (Fig. 3).
Following Dr. Driver, prof. Tal Pupko from the Department of Cell Research &
Immunology, Tel-Aviv University (Tel-Aviv, Israel) focused his talk on the differentialFig. 3 Jane Ann Driver, from Brigham and Women’s Hospital (Boston, MA, USA)
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line, they found (in collaboration with researchers from the Centre Psychiatrie &
Neurosciences, INSERM U894) an important enrichment of positively selected genes in
those pathologies. Positive selection is mainly found when genes drift due to pressures
in new environments. Such work on human-specific gene evolution may point to limi-
tations of using distant animal models, which might have experienced different selec-
tion pressures.
Dr. Hervé Rhinn from the Department of Pathology & Cell Biology, Columbia
University Medical Center (Columbia, NY, USA) then talked about variants in the hu-
man genome linked to the risk of developing non-familial AD and PD. Application of
bioinformatics techniques, such as Differential Co-expression Analysis to whole tran-
scriptome gene expression data, enables the study of expressed and non-expressed gen-
etic components. These tools revealed the role of genetic components in key processes
of neurodegeneration including alpha-synuclein regulation in PD [11] and the impact
of RNF219 gene as a mediator of the effect of APOE-E4 in AD [12].
Prof. Simonneau concluded the second session with a presentation centered on using
protein-protein interactions to understand neuronal diseases. He presented regulatory
networks obtained from large-scale hypothesis-free analysis such as yeast two-hybrids,
whole-genome sequencing and epistatic linkage analysis. These networks linked several
genes identified in Schizophrenia and Late-Onset Alzheimer's disease – Genome-wide
association studies (LOAD-GWAS). He then described his group’s efforts to validate
this network on mouse brain tissue and primary neurons. They used endogenous
immunoprecipitation, proximity ligation assays, electrophysiology and behavior on a
novel transgenic model that overexpresses human BIN1 and thus mimicks BIN1
changes found in LOAD patients. Neurodegenerative pathologies are “network dis-
eases”. The analysis of large networks of physical or functional interactions between
genes and proteins permits to discover new molecular causes to the diseases, better
understand their development and also suggest targets for treatments.
Dr. James Adjaye from the University of Düsseldorf (Düsseldorf, Germany) moder-
ated the third and last session of the Symposium.
The opening talk was given by Prof. Arthur W. Toga from the Center for Computa-
tional Biology, USC (Los Angeles, CA, USA). Prof. Toga leads the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) that produced a unique set of open-access databases
of genetics, biomarkers and imaging [13]. Because of the ever increasing size of existing
and emerging databases, Prof. Toga emphasized the importance of the treatment and
description of the data in order to enable their meaningful comparison and integration.
Shared and unified ontologies are becoming key to validate analysis results obtained
from combining different sources. Integration of genetic and neuroimaging data will be
key to understand Alzheimer's disease. However the linkages are often complex, and
more data is needed, from more patients, for all effects to be detectable. The talk thus
ended with the presentation of the Global Alzheimer’s Association Interactive Network
(GAAIN), a set of analytical tools and computational resources to connect AD scien-
tists worldwide [14]. Such a large scale sharing of data across the world promises to
speed up research on the disease.
Dr. Jean-François Demonet from the Leenaards Memory Centre CHUV, Lausanne
University (Lausanne, Switzerland) then gave a presentation on the role of neuropsychology
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markers. He highlighted the lack of data on diagnosis of ABCDs and called for a set of reli-
able cognitive tests to detect and identify the main conditions. Being able to detect such
diseases early will improve treatment and care.
Dr. Jérôme Dauvillier, from the SIB (Lausanne, Switzerland), discussed the analysis of
epistatic effects - the effect of a genetic variant that depends on the presence of another
genetic variant - to understand the physiopathology of Alzheimer’s Disease. He first de-
scribed an epistatic analysis of two patient cohorts (TGen and HBTRC) based on geno-
typing data linked with the Braak Score (distribution of neurofibrillary tangles). A Gene
Ontology enrichment analysis showed that the epistatic genes are linked to synapses,
axonal guidance, and cell-cell adhesion. Dr. Dauvillier also presented an epistasis ana-
lysis based on whole-genome sequencing and ADNI’s data consortium, providing many
perspectives, taking advantage of their unique computing facilities (ViTal-IT). This kind
of analysis brings information on gene-gene interactions in AD physiopathology by
complementing the more classical approaches of GWAS. Although crucial to under-
stand the complex genetic basis of Alzheimer disease, the number of statistical tests re-
quired by epistatic analyses explodes with the number of variants involved and requires
large amounts of computing power.
This last session ended with a lecture from Dr. Adjaye, who presented his group’s
efforts on investigating disease mechanism using induced Pluripotent Stem Cells (iPSC)
from AD patients [15]. Indeed, direct biochemical observation of living patients is im-
possible. Producing neurons from those patient using reprogrammed cells (generally
blood or skin cells) provided an alternative. Dr Adjaye was able to differentiate the
iPSCs into neuronal cells and to detect the expression of p-Tau and GSK3β. Transcrip-
tome analysis of AD-iPSC derived neuronal cells revealed significant changes in the
expression of genes associated with AD, such as APOE, APP or PSEN. Dr. Adjaye fi-
nally described his group’s work on neuronal cells derived from patient having rare var-
iants of susceptibility genes such as TREM2. Such human cellular models present an
alternative to animal models to understand molecular and cellular aspects of the
dieasse.
Ioannis Xenarios concluded the meeting thanking all the participants of the sympo-
sium (Fig. 4).
Breaks for lunch and refreshments took place around posters, allowing everyone to
ask questions and provide feedback to their authors. The posters covered a large varietyFig. 4 Around 100 researchers attended the meeting symposium
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neurodegeneration or protein overexpression on pathophysiology. Three poster authors
were selected to present their works to the audience. PhD student Wenjia Wang from
PHARNEXT (Issy-Les-Moulineaux, France) took the opportunity to present a multi-
marker genetic association test based on the Rasch model that provides new insights
into the genetics of Alzheimer’s Disease. Claire Lesieur from the École Normale
Supérieure Systèmes Complexes de Lyon IXXI (Lyon, France) talked about natural
“Smart” material from proteins. Computer prediction of conformational changes of
proteins involved in neuronal diseases will lead to engineered folded mutant proteins
able to interact with misfolded forms and avoid their aggregation. Finally, Dr. Lavinia
Alberi from the Unit of Anatomy Department of Medicine - UNIFR (Fribourg,
Switzerland) presented her results suggesting the implication of Notch1 in neural plas-
ticity and neurodegeneration.
This symposium brought together scientists with a variety of expertise around the
theme of human brain complexity and cognitive disorders. Despite aiming towards the
same goal - a better understanding of neurodegenerative conditions -, the speakers pro-
vided the audience with very different but promising approaches. The only commonal-
ities were the need to consider the role of parts within a system, and the interplay
between experimental and computational investigations. For years, the scientific com-
munity has tried to explain complex and multifactorial pathologies like Alzheimer’s dis-
ease by exploring a unique aspect of the pathology (neurodegeneration, immune
defects, metabolism disorders) or the effect of given genes and proteins. Whereas a
more comprehensive approach based on large-scale heterogeneous dataset is certainly
needed. Big Data has entered biologists everyday life, and they tend to generate and use
an every growing amount of such information. This symposium showed how such
high-throughput data, from genotypes to imaging, including gene expression, proteo-
mics, physiological recordings, can be useful to develop new biological hypothesis and
test them in mathematical models. It also showed the huge work that represents data
curation and management. Even if, as Pr. Toga underlined it, one should keep in mind
that these approaches are providing associations and not causalities, Big Data is open-
ing the door to a more translational science, a better communication between the dif-
ferent fields (animal models, clinical trial, mathematics and bioinformatics). This day
was a good representation of such an evolution of scientific research and the associated
promises, as recognized by international organization such as OECD [16]. However,
despite the existence of a so-called data deluge, we do not in fact have enough data to
understand complex pathologies and in particular neurodegenerative diseases. We need
more data, more open, and better integration.Abbreviations
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